Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?

Urology

Volumn 68, Issue 5, 2006, Pages 993-997

  Kuo, Hann Chorng ^a  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; BLADDER CAPACITY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HEMATURIA; HUMAN; MICTURITION DISORDER; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; URINARY TRACT INFECTION; URINE RETENTION; URODYNAMICS;

BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; URINARY BLADDER, OVERACTIVE; UROTHELIUM;

EID: 33750922856     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.05.054     Document Type: Article

References (12)

1. Reitz A., Stohrer M., Kramer G., et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45 (2004) 510-515
2. Kalsi V., Apostolidis A., Popat R., et al. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49 (2006) 528-535
3. Schurch B., de Seze M., Denys P., et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174 (2005) 196-200
4. Rajkumar G.N., Small D.R., Mustafa A.W., et al. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 96 (2005) 848-852
5. Kuo H.C. Clinical effects of suburothelial injection of botulinum A toxin in patients with non-neurogenic detrusor overactivity refractory to anticholinergics. Urology 66 (2005) 94-98
6. Schulte-Baukloh H., Weiss C., Stolze T., et al. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 66 (2005) 82-87
7. Kessler T.M., Danuser H., Schumacher M., et al. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?. Neurourol Urodyn 24 (2005) 231-236
8. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-Committee of the International Continence Society. Neurourol Urodyn 21 (2002) 167-178
9. Apostolidis A., Dasgupta P., and Fowler C.J. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49 (2006) 644-650
10. 3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174 (2005) 977-983
11. Popat R., Apostolidis A., Kalsi V., et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum A toxin. J Urol 174 (2005) 984-989
12. Werner M., Schmid D.M., and Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 192 (2005) 1735-1740